|
|
|
|
|
Everolimus |
|
40-O-(2-hydroxyethyl)-rapamycin |
|
159351-69-6 |
|
Everolimus, a proliferation signal inhibitor, prevents allograft rejection in rodent and non-human primate models of allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation, and thus clonal expansion, of antigen-activated T cells which is driven by T cell-specific interleukins, e.g. interleukin-2 and interleukin-15. Everolimus inhibits an intracellular signaling pathway which is triggered upon binding of these T cell growth factors to their respective receptors, and which normally leads to cell proliferation. The blockage of this signal by everolimus leads to an arrest of the cells at the G1 stage of the cell cycle. |
|
Form: solid powder Color: white to off-white Odor: none Melting point/Melting range: Danger of explosion: none Solubility in / Miscibility with water: not soluble Solvent content: none Organic solvents: soluble in DMSO or methanol
|
Industrial field |
pharmaceutical |
|
|
|
|
|
|
|
There are no existing companies to distribute selected chemical product |
|
|
|
|
|